Quizartinib Dihydrochloride

DRUG4 trials

Sponsors

Fundacion PETHEMA, Fundacion PETHEMA, Daiichi Sankyo, Ruijin Hospital

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia With Gene MutationsHealthy SubjectsNewly diagnosed acute myeloid leukemia patients aged equal or more than 60 years old

Phase 1

A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects

CompletedNCT04796831

Daiichi SankyoHealthy Subjects

Start: 2021-04-26End: 2021-06-11Updated: 2023-01-11

A phase I-II, multicentre, open label clinical trial to assess the safety and tolerability of the combination of low-dose cytarabine or azacitidine, plus Venetoclax and Quizartinib in newly diagnosed acute myeloid leukemia patients aged equal or more than 60 years old ineligible for standard induction chemotherapy

CompletedCTIS2024-519275-26-00

Fundacion PETHEMA, Fundacion PETHEMANewly diagnosed acute myeloid leukemia patients aged equal or more than 60 years old

Start: 2024-11-15End: 2025-09-30Target: 84Updated: 2025-02-25

Phase 2

Study of SA+X in the Treatment of Newly Diagnosed AML

RecruitingNCT07548710

Ruijin HospitalAcute Myeloid Leukemia

Start: 2026-05-01End: 2028-12-21Target: 205Updated: 2026-07-30

Unknown Phase

Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

Daiichi SankyoAcute Myeloid Leukemia With Gene Mutations

Updated: 2020-04-15